Divi's Laboratories Limited

“Divi's Laboratories is among the highest-quality businesses in Indian listed equities — a debt-free, founder-led, process-chemistry-moated CRAMS and generics API manufacturer earning 24% through-cycle ROIC with a long reinvestment runway supported by China+1 tailwinds, patent cliffs, and GLP-1 custom synthesis opportunities. The business deserves a permanent premium. However, at 57x forward earnings and 11.5x book, the market has already capitalized every positive scenario, leaving no margin of safety; a 23% PAT CAGR is required just to earn 12% annual returns from today's entry. The realistic 10-year return is 7-10% CAGR — uninspiring for a concentrated single-stock bet. The one genuine risk of permanent capital loss remains a sustained USFDA action at the concentrated Visakhapatnam complex, which is entirely unpriced at current multiples. Wait for a 25-35% correction to a 35-40x forward earnings entry; the business is not going anywhere.”